An SLP vaccine containing HPV16 E7 antigen in combination with TLR9 agonist CpG formulated in an oil-in-water emulsion was found to inhibit tumor growth and induce robust CD8+ T cell response in TC-1 murine model [173]. This evidence concerns the gene CD8A and neoplasm.